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Commentary
and number and the type of samples needed. The authors also 
noted the diversity of available bioinformatics tools and the 
importance of different computational approaches based on 
variant class and assay design. However, detailed guidance for 
validation of bioinformatics tools was left to a later working 
group.
The most recent publication by Roy et al. provides the much 
needed guidance on the design and use of bioinformatics 
pipelines in clinical NGS. The recommendations in this article 
are informed by a systematic review of 147 publications on 
validation of clinical NGS bioinformatics. This literature 
review again highlighted the dissimilarity of computational 
methods used to align sequence reads and identify variants.
Each of the recent AMP recommendation papers is the result 
of collaboration with other organizations having expertise 
in particular aspects of clinical NGS validation. With its 
focus on bioinformatics, the most recent recommendations 
were formed in partnership with the College of American 
Pathologists (CAP) and the American Medical Informatics 
Association.
Comments
The recommendations in Roy et al. are extensive and address 
the issues of validation, study design, selection of appropriate 
and representative variants, information security, data integrity, 
quality control/quality assurance, and regulatory compliance. 
Throughout, the focus of these recommendations remains on 
the specimen and its associated clinicopathological setting. 
Outside of de facto file format standards, there is no effort to 
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summary
Clinical next‑generation sequencing (NGS) has evolved from a 
novel and promising test modality into a necessary and integral 
part of diagnosis and prediction of response to therapy. The 
technology to implement NGS, while complex, is now within 
the reach of most clinical laboratories. As NGS technology 
has advanced, a variety of professional and regulatory bodies 
have developed guidance for clinical laboratories seeking to 
develop NGS assays [Figure 1].[5,6]
The article by Roy et al. in the January issue of JMD is the 
most recent publication in a series of recommendations for 
clinical NGS[1] led by the Association for Molecular Pathology. 
In earlier JMD papers, Li et al.[2] and Richards et al.[3] 
established the standards for reporting of somatic and germline 
sequence variants, respectively. Their work focused on the best 
practices for selection and use of reference databases and on 
the evidence‑based, clinically focused variant classification. 
Li et al. based their recommendations, in part, on surveys of 
variant classification from Association for Molecular Pathology 
(AMP) member laboratories. These surveys highlighted the 
broad differences not only in how variants were classified  but 
also in the underlying bioinformatics pipelines each laboratory 
used to identify variants.
Targeted oncology sequencing panels are among the most 
popular applications of NGS. Jennings et al. outlined the 
recommendations of a second AMP working group for 
validation of these NGS‑based oncology panels.[4] This paper 
covered panel design, wet laboratory method, and universal 
validation issues such as reproducibility, limit of detection, 
Figure 1: Summary of guidelines and recommendations for clinical next-generation sequencing
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recommend any specific technology. Unlike most clinical testing 
approaches, validating all potential findings (variants) on an 
NGS panel is impractical, and instead, the authors recommend 
that each potential type of variant (single‑nucleotide variant, 
indel, etc.) is validated, along with its respective specialized 
variant caller. Because the number of potential variants is too 
great to validate individually in an analyte‑based approach, the 
choice of an appropriate number of representative variants for 
use in a method‑based validation approach is of considerable 
importance to laboratory directors. To address this issue, 
the authors propose a simple but useful formula based on 
probability and confidence of variant detection.
The 17 recommendations within these guidelines build upon 
the existing CAP molecular checklist by providing a more 
general foundation in bioinformatics and more specific 
guidance for rigorous validation. Directors of established 
clinical NGS laboratories will find agreement with many 
of their current validation practices and will likely also 
identify areas for improvement. For laboratories that are 
implementing clinical NGS testing for the first time, the 
“Standards and Guidelines for Validating Next‑Generation 
Sequencing Bioinformatics Pipelines” is a comprehensive 
guide for all aspects of small sequence variant testing 
from read alignment through variant annotation. The 
focus on single nucleotide and short indel variants is an 
important limitation, as bioinformatics tools to identify 
structural and copy number variants are already in use 
in the clinical laboratory. These tools require their own 
computational approaches and will necessitate additional 
future recommendations.
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